New & Noteworthy

What’s Real in Rare Disease

Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment.

Compliance at the Cross-Border Crossroads

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

HBA Woman of the Year: J&J’s Denice Torres

Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres.

Biosimilars Ramp-Up: Five Themes for the Future

The task of imitating substantially complex molecular entities offers up a host of new operational questions for pharma.

Evaluating the Impact of the Falsified Medicines Directive in Switzerland

As the prevalence of falsified medicines increases, Switzerland is taking measures to secure its supply chain.

Europe

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

Evaluating the Impact of the Falsified Medicines Directive in Switzerland

As the prevalence of falsified medicines increases, Switzerland is taking measures to secure its supply chain.

The NHS's Meningitis B Vaccine Deal with GSK: A Slow Step in the Right Direction

That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham.

Europe: Researching New Drugs "Needs Research into New Pricing Systems"

In Europe drug pricing concerns are continuing to invade the hitherto sacrosanct territory of drug development, writes Peter O'Donnell.

Global

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

The Goods and Services Tax: A Bane or a Boon for Indian Pharma?

Dr. Anuj Gupta explains the potential implications of the GST— or the goods and services tax — on Indian pharma.

Europe: Researching New Drugs "Needs Research into New Pricing Systems"

In Europe drug pricing concerns are continuing to invade the hitherto sacrosanct territory of drug development, writes Peter O'Donnell.

Strategy

Behind the Boom in Biotech

Pharm Exec recently convened a roundtable discussion with nine company aspirants for leadership in the hard science of small biotech.

Regulatory Information Management as a Strategic Asset

Adam Sherlock looks at why pharma companies have started taking regulatory information management (RIM) more seriously.

Pharma 2015: Industry in Flux

What's hot and what's not this year? Is pharma still a 21st century growth industry? See our 2015 Strategic Outlook.

PEspeaks

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

The UK Election's Hot Healthcare Topics

Leela Barham looks at what the rival parties are promising for healthcare ahead of the UK General Election next month.

A New CellTx Index?

Casey McDonald asks, is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Are Times A’Changing for Drug Marketing?

FDA is under pressure to moderate oversight of pharma advertising and promotion.

UnitedHealth’s Acquisition of PBM Catamaran Heralds Escalating Price War With Drugmakers

The announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.

Regulatory

Congress, White House Seek to Spur Biomedical Innovation

The productivity of the U.S. biomedical research enterprise is undergoing a broad re-examination.

Public Opinion Matters—And Merits Attention

Media rebuke of Europe’s Innovative Medicines Initiative thrusts debate into the public arena.

Accelerated Change: Understanding the FDA’s Expedited Pathways

Jamie Gault outlines the key differentiators between each of FDA's programs to facilitate and expedite drug development and review of new drugs.

Pharma Company Disclosures Draw SEC Scrutiny

The Securities and Exchange Commission (SEC) is focusing more on the accuracy and timeliness of biopharma company financial filings, particularly those related to regulatory actions involving FDA, writes Jill Wechsler.

Sales & Marketing

Data is Now the Key to Marketing

Neil Gleghorn, looks at the upsurge of technology and metric-driven marketing operations in the strictly regulated pharmaceutical industries.

Are Times A-Changing for Drug Marketing?

FDA is under pressure to moderate oversight of pharma advertising and promotion, writes Jill Wechsler.

So What is Pharma’s Ideal Role in Social?

Advertorial: Ashfield Commercial & Medical Services believes that Pharma can use social media to play an important role in educating the healthcare professional (HCP) and the patient

Democratizing Access to Healthcare with Technology

PharmExec talks to babylon founder and CEO Ali Parsa on how technology will deliver healthcare services to patients globally.